Ipilimumab-induced hypophysitis: MR imaging findings.
Ipilimumab is a promising new immunotherapeutic antineoplastic agent with clinical activity in the treatment of metastatic melanoma and renal cell carcinoma. With advances in immunotherapy, however, a host of new side effects related to the mechanism of action of these drugs has appeared. At our institution, 3 patients presented with hypophysitis, which was attributed to an autoimmune process based on the documented relationship of the drug to other autoimmune phenomena and significant and rapid improvement with discontinuation of the drug and addition of steroids. We present the imaging findings in 3 patients with presumed ipilimumab-induced hypophysitis.
Carpenter
K J
KJ
Department of Radiology, University of South Florida, Tampa, FL 33629, USA.
Murtagh
R D
RD
Lilienfeld
H
H
Weber
J
J
Murtagh
F R
FR
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001921:Brain / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010900:Pituitary Diseases / Q000139:chemically induced* / Q000473:pathology*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab